MedElevator
Войти в исследования JACC. Case reports · 2026
Valve-in-Valve Implantation for Early Failure of a Transcatheter Tricuspid Valve.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Boukantar Madjid, Aouate David, Chiaroni Paul-Matthieu, Zamora Patrick, Truong Tony, Molho Antoine, Labidi Oueies, Boyer Clement, Teiger Emmanuel, Gallet Romain
Аннотация
BACKGROUND: Transcatheter tricuspid valve replacement (TTVR) is increasingly used for severe tricuspid regurgitation in high-risk patients. Early prosthetic dysfunction may occur, but management strategies remain poorly described.
CASE SUMMARY: A 79-year-old woman presented with cardiogenic shock 6 months after Topaz TTVR. Echocardiography and computed tomography showed leaflet thickening involving 2 of 3 leaflets with a mean gradient of 9 mm Hg. Endocarditis was excluded, and anticoagulation optimization failed. Because of persistent catecholamine dependence and prohibitive surgical risk, the heart team selected transcatheter valve-in-valve implantation. Bench testing using a computed tomography-derived 3-dimensional printed model guided a 29-mm Sapien 3 valve implantation, reducing the gradient to 1 mm Hg with no residual regurgitation.
DISCUSSION: Valve-in-valve implantation may be an effective rescue strategy after failed TTVR. Patient-specific bench testing improves procedural planning and procedural safety.
TAKE-HOME MESSAGES: Early dysfunction of TTVR prostheses requires prompt multimodality evaluation. Bench-guided transcatheter valve-in-valve implantation can safely avoid high-risk redo surgery.
CASE SUMMARY: A 79-year-old woman presented with cardiogenic shock 6 months after Topaz TTVR. Echocardiography and computed tomography showed leaflet thickening involving 2 of 3 leaflets with a mean gradient of 9 mm Hg. Endocarditis was excluded, and anticoagulation optimization failed. Because of persistent catecholamine dependence and prohibitive surgical risk, the heart team selected transcatheter valve-in-valve implantation. Bench testing using a computed tomography-derived 3-dimensional printed model guided a 29-mm Sapien 3 valve implantation, reducing the gradient to 1 mm Hg with no residual regurgitation.
DISCUSSION: Valve-in-valve implantation may be an effective rescue strategy after failed TTVR. Patient-specific bench testing improves procedural planning and procedural safety.
TAKE-HOME MESSAGES: Early dysfunction of TTVR prostheses requires prompt multimodality evaluation. Bench-guided transcatheter valve-in-valve implantation can safely avoid high-risk redo surgery.